Skip to main content
Top

09-07-2018 | Systemic lupus erythematosus | Article

Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus

Journal: Clinical Rheumatology

Authors: Chengcheng Hou, Ou Jin, Xi Zhang

Publisher: Springer London

Abstract

To investigate the clinical characteristics of infection in SLE patients and analyze the risk factors of infection. A retrospective analysis method was used and the data were collected from 173 case times of 142 hospitalized patients. We found the incidence rate of infections in SLE was 50.7%. The most common infection sites were lungs, followed by upper respiratory tracts and urinary tracts. The most common pathogens were bacteria, followed by fungi. The infection-associated risk factors were duration of hospitalization, lupus activity state, the use of high-dose corticosteroids and immunosuppressive agents, the low serum level of complements 3 and 4 (C3 and C4), fever, the high level of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), the abnormality of white blood cell (< 4 × 109/L or > 10 × 109/L), and the low level of albumin (P < 0.05 or P < 0.001). The independent risk factors for SLE patients with infection consist of the abnormality of white blood cells, the high level of CRP, the low serum level of C4, and longtime hospitalization. Attention should be paid to the risk factors of infection, and treatment to enhance immunity should be carried out to reduce the chance of infection.
Literature
1.
Dubula T, Mody GM (2015) Spectrum of infections and outcome among hospitalized South Africans with systemic lupus erythematosus. Clin Rheumatol 34(3):479–488CrossRefPubMed
2.
Wu L, Wang X, Chen F, Lv X, Sun W, Guo Y, Hou H, Ji H, Wei W, Gong L (2017) T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients. Braz J Med Biol Res 51(2):e4547PubMedPubMedCentral
3.
Jung JY, Suh CH (2017) Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med 32(3):429–438CrossRefPubMedPubMedCentral
4.
Wang KC, Liu PH, Yu KH, Weng YM, Ng CJ, Chiu TF, Chen SY (2017) Is initial C-reactive protein level associated with corticosteroid use in lupus erythematosus patients during a bacterial infection episode? Immunol Lett 185:84–89CrossRefPubMed
5.
Lin H, Wei JC, Tan CY, Liu YY, Li YH, Li FX (2012) Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China. Clin Rheumatol 31:1683–1689CrossRefPubMed
6.
Chen CH, Tai SB, Chen HC, Yang DH, Peng MY, Lin YF (2015) Analysis of erythrocyte C4d to complement receptor 1 ratio: use in distinguishing between infection and flare-up in febrile patients with systemic lupus erythematosus. Biomed Res Int 2015:939783PubMedPubMedCentral
7.
Hahn BH, Mcmahon MA, Wilkinson A (2012) American College of Rheumatology guidelines for guidelines for screening, treatment, and management of lupus nephritis [J]. Arthritis Care Res 64(6):797–808CrossRef
8.
Badr G, Sayed A, Abdel-Maksoud MA, Mohamed AO, El-Amir A, Abdel-Ghaffar FA, Al-Quraishy S, Mahmoud MH (2015) Infection of female BWF1 lupus mice with malaria parasite attenuates B cell autoreactivity by modulating the CXCL12/CXCR4 Axis and its downstream signals PI3K/AKT, NFκB and ERK. PLoS One 10(4):e0125340CrossRefPubMedPubMedCentral
9.
Wu SA, Yeh KW, Lee WI, Yao TC, Kuo ML, Huang B, Huang JL (2013) Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus 22(3):279–288CrossRefPubMed
10.
Cervera R, Khamashta MA, Font J (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82:299–308CrossRef
11.
Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res 66:608–616CrossRef
12.
Tektonidou MG, Wang Z, Dasgupta A, Ward MM (2015) Burden of serious infections in adults with systemic lupus erythematosus: a National Population-Based Study, 1996–2011. Arthritis Care Res 67(8):1078–1085CrossRef
13.
Han BK, Bhatia R, Traisak P (2013) Clinical presentations and outcomes of systemic lupus erythematosus patients with infection admitted to the intensive care unit. Lupus 22(7):690–696CrossRefPubMed
14.
Ekwom PE (2013) Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital. Clin Rheumatol 32(8):1215–1217CrossRefPubMed
15.
Jeong SJ, Choi H, Lee HS, Han SH, Chin BS, Baek JH, Kim CO, Choi JY, Song YG, Kim JM (2009) Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 41(4):268–274CrossRefPubMed
16.
Chen D, Xie J, Chen H, Yang Y, Zhan Z, Liang L, Yang X (2016) Infection in southern Chinese patients with systemic lupus erythematosus: spectrum, drug resistance, outcomes, and risk factors. J Rheumatol 43(9):1650–1656CrossRefPubMed
17.
Goldblatt F, Chambers S, Rahman A, Isenberg DA (2009) Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 18:682–689CrossRefPubMed
18.
Bosch X, Guilabert A, Pallarés L, Cervera R, Ramos-Casals M, Bové A, Ingelmo M, Font J (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589CrossRefPubMed
19.
Danza A, Ruiz-Irastorza G (2013) Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 22:1286–1294CrossRefPubMed
20.
Tse KC, Tang CS, Lam MF, Yap DY, Chan TM (2009) Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 36(1):76–81PubMed
21.
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11(4):R109CrossRefPubMedPubMedCentral
22.
Navarro-Zarza J, Alvarez-Hernandez E, Casasola-Vargas J et al (2010) Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. Lupus 19(1):43–48CrossRefPubMed
23.
Tse KC, Tang CS, Lio WI, Lam MF, Chan TM (2006) Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid and oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15(6):371–379CrossRefPubMed